ReviewCurrent medical science2025
miR-146a Regulates Neuroinflammation and Immune Cell Function in Neurodegenerative Diseases.
Review in Current medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- SerumInternational journal of molecular sciences · 2026Article
- PAR-1 in Alzheimer's Disease: Pathophysiological Insights and Mechanistic Perspectives.Current medical science · 2026Review
- Causal associations between cognitive impairments and retinal diseases: A two-sample Mendelian randomization study.The Journal of international medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Neurodegenerative diseases (NDDs) are characterized primarily by progressive impairments in cognition, behavior, and memory. MicroRNAs (miRNAs) are abundantly expressed in the central nervous system and are vital for the normal function and survival of neurons. Mature miRNAs are naturally occurring small noncoding single-stranded RNA molecules that are approximately 21-25 nucleotides in length. They regulate gene expression by pairing with target mRNAs and undergo significant alterations in various physiological and pathological processes. miR-146a, a miRNA dependent on nuclear factor κB (NF-κB), is highly expressed in neurons and functions as an anti-inflammatory miRNA via the Toll-like receptor (TLR) pathway, which is an essential regulatory factor for neuroinflammation expression during the development of NDDs. In this review, we summarize and emphasize the pivotal role of miR-146a in NDDs, highlighting the association between miR-146a polymorphisms and the risk of NDDs. We also discuss how alterations in miR-146a expression levels represent a critical event in the pathogenesis of numerous NDDs. Furthermore, the target genes of miR-146a are involved in regulating the pathophysiological processes of these diseases, particularly in the context of neuroinflammatory responses. In conclusion, miR-146a plays a central role in the progression of NDDs, with its primary function in neuroinflammation. These findings suggest that miR-146a holds promise as both a biomarker and a potential therapeutic target. A deeper understanding of how miR-146a influences neuroinflammatory responses across different types of neurological damage, cell types, and even various stages of certain NDDs will pave the way for its use as a therapeutic target in treating these conditions. Therefore, this article reviews the mechanism of miR-146a in NDDs and discusses the future therapeutic prospects for this type of disease. miR-146a regulates the related genes of the inflammatory signaling pathway and its influence on the development of NDDs. (Created in https://BioRender.com ).
Indexed as
Identifiers
40632438What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.